
Combining a personalized mRNA-based cancer vaccine with pembrolizumab improves recurrence-free survival in high-risk melanoma patients.


coremsg

Combining Moderna's patient-specific mRNA-based cancer vaccine with pembrolizumab may prolong recurrence-free survival in patients with high-risk melanoma vs pembrolizumab alone, new data show.

'Exciting' Results for Cancer Vaccine Plus Pembro in Melanoma

positive-results-for-cancer-vaccine-plus-pembrolizumab-in-melanoma


Positive Results for Cancer Vaccine Plus Pembrolizumab in Melanoma
